期刊文献+

Effects of Sunitinib Malate on Growth of Human Bladder Transitional Cell Line T24 In Vitro 被引量:1

Effects of Sunitinib Malate on Growth of Human Bladder Transitional Cell Line T24 In Vitro
下载PDF
导出
摘要 Objective To investigate the growth-inhibitory effect of sunitinib malate on human bladder transitional cell carcinoma (TCC) in vitro. Methods Human bladder TCC cell line T24 was cultured and exposed to graded concentrations of sunitinib malate for 72 hours in vitro to determine the sensitivities to drug. Cell viability was measured by MTT assay. Cell apoptotic morphology was observed by fluorescence microscope following DAPl staining. Band expressions of Fas, Fas ligand, poly (ADP-ribose) polyrnerase (PARP) and D-actin were analyzed by Western blot. Wound healing process of T24 cells exposed to sunitinib malate was assayed. Results Sunitinib malate exerted a concentration-dependent and time-dependent inhibitory effect on the T24 cell lines. Fluorescence microscopy showed that small vacuoles appeared in the nuclei of T24 cells and the vacuoles were bigger with higher drug concentrations. The expressions of Fas ligand and PARP in T24 cells treated with sunitinib malate exhibited a concentration-dependent increase. Moreover sunitinib malate suppressed the wound healing process in a concentration-dependent manner. Conclusion Sunitinib malate exerted marked inhibitory activity against bladder cancer cell line T24.
出处 《Chinese Medical Sciences Journal》 CAS CSCD 2015年第1期51-55,共5页 中国医学科学杂志(英文版)
基金 Supported by the Beijing Natural Science Foundation(7102128)
关键词 SUNITINIB bladder cancer PROLIFERATION 体外生长 细胞系 苹果酸 膀胱癌 移行 浓度依赖性 生长抑制作用 Fas配体
  • 相关文献

参考文献8

  • 1Ballas MS, Chachoua A. Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC. Onco Targets Ther 2011; 4:43-58.
  • 2Petrillo M, Scambia G, Ferrandina G. Novel targets for VEGF-independent anti-angiogenic drugs. Expert Opin Investig Drugs 2012;21:451-72.
  • 3Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295:2516-24.
  • 4Tran TA, Kinch L, Peffa-Llopis S. Platelet-derived growth factor/vascular endothelial growth factor receptor inactivation by sunitinib results in Tscl/Tsc2-dependent inhibition of TORC1. Mol Cell Biol 2013; 33:3762-79.
  • 5Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase Ⅱ trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008; 26:650-6.
  • 6Wu CL, Ping SY, Yu CP, et al. Tyrosine kinase receptor inhibitor-targeted combined chemotherapy for metastatic bladder cancer. Kaohsiung J Med Sci 2012; 28:194-203.
  • 7Kim S, Ding W, Zhang L, et al. Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: A review of clinical trials. Onco Targets Ther 2014; 12:719-28.
  • 8Szarvas T, Jager T, Droste F, et al. Serum levels of angiogenic factors and their prognostic relevance in bladder cancer. Pathol Oncol Res 2009; 15:193-201.

同被引文献1

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部